Get access

Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab

Authors

  • Rajkumar Venkatramani MD, MS,

    Corresponding author
    1. Division of Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, California
    2. Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California
    • Correspondence to: Rajkumar Venkatramani, Assistant Professor of Pediatrics, Division of Hematology/Oncology, Children's Hospital Los Angeles, 4650, Sunset Boulevard, Mailstop 54, Los Angeles, CA 90027.

      E-mail: rvenkatramani@chla.usc.edu

    Search for more papers by this author
  • Marcio H. Malogolowkin MD,

    1. Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin
    Search for more papers by this author
  • Leo Mascarenhas MD, MS

    1. Division of Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, California
    2. Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California
    Search for more papers by this author

  • Conflict of interest: Nothing to declare.

Abstract

As most active chemotherapy agents against Wilms tumor are incorporated into upfront therapy, particularly for those patients with high risk for recurrence, novel regimens are needed to treat children with relapsed Wilms tumor. We describe four consecutive patients with multiply relapsed Wilms tumor who were treated with a combination of vincristine, irinotecan, temozolomide, and bevacizumab. Two had a complete response, and two had a partial response to treatment. Hematological toxicity and diarrhea were the main side effects. This regimen has activity in patients with multiply relapsed Wilms tumor without excessive toxicity, and should be evaluated further in this setting. Pediatr Blood Cancer 2014;61:756–759. © 2013 Wiley Periodicals, Inc.

Ancillary